Rein Therapeutics (RNTX) Change in Accured Expenses (2016 - 2026)
Rein Therapeutics (RNTX) posted quarterly Change in Accured Expenses of $247000.0 for Q1 2026, up 2570.0% year-over-year from $9250.9 in Q1 2025, and down 57.71% quarter-over-quarter from $584000.0 in Q4 2025.
Rein Therapeutics (RNTX) Change in Accured Expenses (2016 - 2026) Analysis & Trends
Rein Therapeutics (RNTX) has reported Change in Accured Expenses for 11 consecutive years, with $247000.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Change in Accured Expenses rose 2570.0% year-over-year to $247000.0; the TTM figure through Mar 2026 stood at -$2.4 million (down 196.45% YoY), while the FY2025 annual figure was -$2.6 million, down 255.06% from the prior year.
- Change in Accured Expenses declined to $247000.0 in Q1 2026 per RNTX's latest filing, from $584000.0 in the prior quarter.
- Across five years, Change in Accured Expenses topped out at $1.8 million in Q2 2024 and bottomed at -$3.2 million in Q2 2025.
- Historically, Change in Accured Expenses has averaged -$155294.1 across 5 years, with a median of $109000.0 in 2023.
- Annual changes were most pronounced in 2022 — Change in Accured Expenses plunged 737.61% — and 2026, when it jumped 2570.0%.
- Rein Therapeutics' Change in Accured Expenses stood at -$1.9 million in 2022, then surged by 105.76% to $109000.0 in 2023, then surged by 136.7% to $258000.0 in 2024, then surged by 126.36% to $584000.0 in 2025, then tumbled by 57.71% to $247000.0 in 2026.
- Business Quant data shows RNTX's Change in Accured Expenses at $247000.0 in Q1 2026, $584000.0 in Q4 2025, and -$34000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Accured Expenses (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 222.50 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 492.70 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 11.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 212.44 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 61.62 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 68.82 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Rein Therapeutics | 55.49 Mn | 55.49 Mn | - | -909,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -909,000.00 |
| Jun 30, 2026 | -909,000.00 |
| Mar 31, 2026 | 247,000.00 |
| Mar 31, 2026 | 247,000.00 |
| Dec 31, 2025 | 584,000.00 |
| Dec 31, 2025 | 584,000.00 |
| Sep 30, 2025 | -34,000.00 |
| Sep 30, 2025 | -34,000.00 |
| Jun 30, 2025 | -3.16 Mn |
| Jun 30, 2025 | -3.16 Mn |
| Mar 31, 2025 | -10,000.00 |
| Mar 31, 2025 | -10,000.00 |
| Dec 31, 2024 | 258,000.00 |
| Dec 31, 2024 | 258,000.00 |
| Sep 30, 2024 | 426,000.00 |
| Sep 30, 2024 | 426,000.00 |
| Jun 30, 2024 | 1.78 Mn |
| Jun 30, 2024 | 1.78 Mn |
| Mar 31, 2024 | -771,000.00 |
| Mar 31, 2024 | -771,000.00 |